STOCK TITAN

Phathom Pharmaceuticals Inc - PHAT STOCK NEWS

Welcome to our dedicated news page for Phathom Pharmaceuticals (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Phathom Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Phathom Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.49%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.7%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.81%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
Phathom Pharmaceuticals Inc

Nasdaq:PHAT

PHAT Rankings

PHAT Stock Data

592.96M
42.90M
8.81%
87.86%
18.21%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Florham Park

About PHAT

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.